164 related articles for article (PubMed ID: 37959379)
1. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
Hida Y; Imamura T; Kinugawa K
J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
[TBL] [Abstract][Full Text] [Related]
3. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Komiya I; Yamamoto A; Sunakawa S; Wakugami T
Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
[TBL] [Abstract][Full Text] [Related]
4. Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio.
Imamura T; Narang N; Kinugawa K
J Clin Med; 2022 May; 11(10):. PubMed ID: 35628945
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
Hirano T; Hayashi T; Sugita H; Tamasawa A; Goto S; Tomoyasu M; Yamamoto T; Ohara M; Terasaki M; Kushima H; Ito Y; Yamagishi SI; Mori Y
J Diabetes Investig; 2023 Dec; 14(12):1401-1411. PubMed ID: 37647503
[TBL] [Abstract][Full Text] [Related]
6. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
Iitake C; Iitake K
J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Small Dense Low-density Lipoprotein-cholesterol Concentration Estimated via Sampson's Equation in Healthy Subjects and Patients with Diabetes.
Hirano T; Ito Y
J Atheroscler Thromb; 2023 Aug; 30(8):979-989. PubMed ID: 36216531
[TBL] [Abstract][Full Text] [Related]
8. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
9. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.
Bando H; Taneda S; Manda N
JMA J; 2021 Apr; 4(2):135-140. PubMed ID: 33997447
[TBL] [Abstract][Full Text] [Related]
12. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
[TBL] [Abstract][Full Text] [Related]
13. Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events.
Izumida T; Imamura T; Narang N; Kinugawa K
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614823
[TBL] [Abstract][Full Text] [Related]
14. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations.
Vargas-Vázquez A; Bello-Chavolla OY; Antonio-Villa NE; Mehta R; Cruz-Bautista I; Aguilar-Salinas CA
Lipids Health Dis; 2021 May; 20(1):46. PubMed ID: 33952259
[TBL] [Abstract][Full Text] [Related]
17. The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: Implications for the negative results of the PROMINENT trial.
Hirano T; Ito Y
J Diabetes Investig; 2023 Jul; 14(7):902-906. PubMed ID: 37016542
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
[TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
